Turning Point Therapeutics Announces Positie Topline Data By Blinded Independent Central Review For Repotrectinib Across All ROS1-positive NSCLC Cohorts Of Phase 1/2 TRIDENT-1 Study
Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study
In a total of 71 TKI-naïve
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
Trevi Therapeutics (NASDAQ:TRVI) stock moved upwards by 11.9% to $1.41 during Friday's after-market session. The market value of their outstanding shares is at $36.4 million.
Stifel Maintains Hold on Turning Point, Lowers Price Target to $45
Stifel analyst Bradley Canino maintains Turning Point (NASDAQ:TPTX) with a Hold and lowers the price target from $50 to $45.
Turning Point Q4 EPS $(1.58) Down From $(1.02) YoY
Turning Point (NASDAQ:TPTX) reported quarterly losses of $(1.58) per share. This is a 54.9 percent decrease over losses of $(1.02) per share from the same period last year.
Oppenheimer Maintains Outperform on Turning Point, Lowers Price Target to $105
Oppenheimer analyst Matthew Biegler maintains Turning Point (NASDAQ:TPTX) with a Outperform and lowers the price target from $115 to $105.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
